Gilead Sciences: The Company That Cured Its Own Market

A structural look at how curing a disease created the most dramatic boom-and-bust cycle in pharmaceutical history and forced a structural reinvention of the company that achieved it.

Introduction

Gilead Sciences (gild) occupies a singular position in pharmaceutical history: it is the definitive case study of the cure paradox, the structural observation that a curative therapy eliminates future demand for itself.

The hepatitis C franchise — Sovaldi and Harvoni — generated nearly $20 billion in combined peak-year revenue in 2015, a commercial achievement without precedent in the drug industry. And then it contracted, rapidly and irreversibly, because the drugs worked. Patients were cured. The treatable population shrank. The revenue curve that had ascended at a velocity never before seen in pharmaceuticals descended with comparable speed.

What makes Gilead structurally interesting beyond the hepatitis C episode is how the company responded to the revenue contraction. The HCV windfall generated tens of billions in cash, and the capital allocation decisions Gilead made with that cash — massive share buybacks, the $11.9 billion Kite Pharma acquisition for CAR-T cell therapy, the $21 billion Immunomedics acquisition for the antibody-drug conjugate Trodelvy — defined a multi-year strategic pivot from a virology-centric company to one attempting to build a durable presence in oncology. Simultaneously, the HIV franchise — anchored by Biktarvy, which commands over 50% of the U.S. treatment market — evolved into the company's structural backbone, providing the steady, recurring revenue that the hepatitis C franchise could not sustain. Understanding Gilead requires seeing all of these dynamics as interconnected: the cure paradox, the capital deployment decisions, the HIV franchise's durability, and the oncology pivot's uncertain trajectory.

The broader structural lesson Gilead offers is about the relationship between therapeutic modality and business model sustainability. Companies that treat chronic conditions — diabetes, HIV, autoimmune disease — build recurring revenue streams that compound over time as the treated population grows. Companies that cure diseases face a fundamentally different dynamic: the commercial opportunity is intense but finite. Gilead has operated on both sides of this divide, and its trajectory illustrates how these different dynamics shape capital allocation, strategic planning, and long-term company identity in ways that quarterly earnings cannot fully capture.

The Long-Term Arc

Founding and the Antiviral Identity (1987 - 2001)

Gilead Sciences was founded in 1987 by Michael Riordan, a physician and Harvard Business School graduate whose interest in antiviral medicine was reportedly sparked by contracting dengue fever while traveling. Originally incorporated under the temporary name Oligogen due to a trademark issue, the company adopted the Gilead Sciences name shortly afterward and established its headquarters in Foster City, California — a location in the San Francisco Bay Area that placed it within the emerging biotechnology ecosystem but distinct from the more established clusters in South San Francisco and the East Bay.

The company's early strategic direction centered on nucleotide analogs — small molecules designed to interfere with viral replication by mimicking the building blocks of DNA and RNA. In 1991, Gilead in-licensed a group of nucleotide compounds including tenofovir, a decision that would prove foundational. Tenofovir's antiviral activity against both HIV and hepatitis B virus positioned Gilead at the intersection of two large and growing viral disease markets. The IPO in January 1992 raised $86 million, providing capital for clinical development during the years when revenue remained negligible and the company operated purely on the promise of its antiviral platform.

The late 1990s and early 2000s saw Gilead's antiviral strategy begin to produce commercially viable products. Viread (tenofovir disoproxil fumarate), approved in 2001 for HIV treatment, was the first major commercial milestone. The drug was not revolutionary in isolation — the HIV treatment landscape already included multiple nucleoside reverse transcriptase inhibitors — but tenofovir's efficacy profile and tolerability established Gilead as a credible player in the HIV treatment market. The antiviral focus was not accidental; it reflected a deliberate strategic bet that virology would be the therapeutic area where Gilead could build competitive advantages in nucleotide chemistry and formulation science. This bet would pay off spectacularly, but the magnitude of the payoff was not yet visible.

Hepsera (adefovir dipivoxil), approved in 2002 for chronic hepatitis B, further reinforced Gilead's antiviral identity and demonstrated the company's ability to develop nucleotide analogs across multiple viral targets. The hepatitis B market was smaller than HIV, but Hepsera's approval validated the scientific platform and built institutional expertise in liver disease that would prove critical when the hepatitis C opportunity arrived a decade later. The early product portfolio — Viread, Hepsera, and the antifungal AmBisome (acquired through the purchase of NeXstar Pharmaceuticals in 1999) — generated modest but growing revenue that sustained the company through its transition from research-stage to commercial enterprise. By the mid-2000s, Gilead was profitable and growing, but it remained a mid-cap biotechnology company — a fraction of the size it would become once the HIV combination strategy and hepatitis C revolution transformed its scale.

Building the HIV Franchise (2001 - 2012)

Gilead's HIV franchise was built through a strategy of progressive combination therapy — developing fixed-dose combinations that simplified treatment regimens from multiple pills taken at various times to a single daily tablet. This approach addressed a real clinical need. HIV treatment adherence was — and remains — critically important; missed doses can lead to viral resistance, treatment failure, and disease progression. Reducing pill burden directly improved adherence, and Gilead recognized that the company controlling the backbone of the combination regimen would capture a disproportionate share of the market's economics.

Truvada, approved in 2004, combined tenofovir with emtricitabine into a two-drug fixed-dose pill that became the standard backbone of HIV combination therapy. Atripla, approved in 2006 in partnership with Bristol-Myers Squibb, added efavirenz to create the first complete single-tablet HIV regimen. These products did not merely generate revenue — they restructured how HIV was treated. Physicians could prescribe a single pill where multiple had been required, and Gilead's tenofovir backbone was embedded in the dominant treatment paradigm. Each successive combination product reinforced the centrality of Gilead's chemistry to HIV care.

The HIV franchise grew steadily through the late 2000s and early 2010s with additional products: Complera (2011), Stribild (2012), and eventually the tenofovir alafenamide (TAF) reformulation that would later anchor Descovy and Biktarvy. The TAF platform represented a meaningful pharmacological improvement — lower doses achieved comparable antiviral efficacy with reduced kidney and bone toxicity compared to the older tenofovir disoproxil fumarate formulation — and it provided a lifecycle management mechanism that extended Gilead's franchise position. By the early 2010s, HIV had become a chronic, manageable condition for patients with access to antiretroviral therapy, and Gilead's products were at the center of that treatment paradigm. The HIV franchise was generating billions in annual revenue with the recurring economics of chronic disease treatment — the structural opposite of what the hepatitis C franchise would soon demonstrate.

The PrEP (pre-exposure prophylaxis) indication added another dimension. The FDA approved Truvada for HIV prevention in 2012, expanding the addressable market from people living with HIV to people at risk of contracting it. This was structurally significant: PrEP created a new patient population that would take Gilead's drugs indefinitely as a preventive measure, not merely until a treatment course was complete. The PrEP market would grow substantially over the following decade, and Gilead's position as the dominant PrEP supplier added a growth vector that was independent of the treatment market's dynamics. The strategic significance of PrEP extended beyond its direct revenue contribution: it meant that Gilead's HIV franchise was no longer bounded by the existing infected population. Prevention created a second addressable market — the at-risk population — that was orders of magnitude larger than the treatment market alone and that would grow as awareness of PrEP expanded and public health systems incorporated it into their HIV control strategies.

The Hepatitis C Revolution (2012 - 2016)

In January 2012, Gilead acquired Pharmasset for $11.2 billion — a price that raised eyebrows across the pharmaceutical industry. Pharmasset was a small company with no marketed products and a market capitalization that had recently been a fraction of the acquisition price. What it possessed was sofosbuvir (PSI-7977), a nucleotide analog that showed unprecedented efficacy against hepatitis C virus. In clinical trials, sofosbuvir-based regimens cured hepatitis C in the vast majority of patients — cure rates exceeding 90% across multiple genotypes, achieved with oral-only regimens lasting 12 weeks. This was a categorical change from the prior standard of care, which involved interferon injections with severe side effects, treatment durations of 24 to 48 weeks, and cure rates that varied widely by genotype and often fell below 50%.

Sovaldi (sofosbuvir) received FDA approval in December 2013, and Harvoni (sofosbuvir plus ledipasvir) followed in October 2014. The commercial launch was explosive. Sovaldi was priced at $84,000 per 12-week treatment course — roughly $1,000 per pill — a pricing decision that generated immediate and sustained political controversy but also reflected the curative nature of the therapy and the total cost savings relative to decades of chronic hepatitis C management, liver transplants, and hepatocellular carcinoma treatment. Harvoni, priced at approximately $94,500 per course, offered a single-tablet regimen that cured the most common genotype of hepatitis C without requiring the addition of ribavirin.

The revenue numbers were staggering. In 2014, Gilead's hepatitis C products generated approximately $12.4 billion in sales. In 2015, the combined HCV franchise peaked at approximately $19.1 billion. The company's total revenue reached $32.6 billion in 2015, up from $11.2 billion just two years earlier. No pharmaceutical company had ever experienced revenue growth of this magnitude and velocity from a single therapeutic area. Gilead's market capitalization surged past $150 billion, briefly making it one of the most valuable pharmaceutical companies in the world.

The political and public health dimensions of the hepatitis C franchise were as significant as the commercial ones. The $84,000 price tag triggered Congressional investigations, with a 2015 Senate Finance Committee report documenting that Gilead's pricing strategy was revenue-driven rather than cost-based. Public health systems — prisons, Medicaid programs, the Veterans Administration — faced the paradox of having a cure available that their budgets could not accommodate for all eligible patients. Some systems rationed access, treating only the sickest patients first. The pricing controversy became a defining episode in the broader pharmaceutical pricing debate and shaped public perception of Gilead in ways that persisted long after the HCV revenue had declined. The structural irony was inescapable: a drug that offered genuine curative value — eliminating the need for decades of chronic hepatitis C management, preventing liver cirrhosis, transplants, and cancer — triggered more pricing backlash than chronic treatments costing comparable cumulative amounts over years of therapy. The concentrated cost of a cure made the price visible in a way that amortized chronic treatment costs did not, revealing how the structure of healthcare payment systems — designed around ongoing treatment expenditures — struggled to accommodate the economics of one-time curative interventions.

The Cure Paradox and Revenue Contraction (2016 - 2019)

The structural dynamics of curative therapy asserted themselves with mechanical precision. Each patient cured was a patient who would never need treatment again. The initial surge of pent-up demand — millions of patients who had been diagnosed with hepatitis C but had been waiting for better treatment options — was absorbed within two to three years of Sovaldi's launch. New diagnosis rates, while ongoing, could not replace the volume of the initial bolus. Competition arrived from AbbVie (abbv) with Viekira Pak and later Mavyret, and from Merck (mrk) with Zepatier, compressing both pricing and market share. The combination of a shrinking treatable population and intensifying competition created a revenue decline that was steep and sustained.

HCV revenue fell from the $19.1 billion peak in 2015 to approximately $9.1 billion in 2017, and continued declining to roughly $3 billion by 2019. Gilead's total revenue contracted from $32.6 billion in 2015 to approximately $22 billion in 2018. The stock price, which had peaked above $120 per share in mid-2015, declined below $60 by late 2016. The market was repricing not just the HCV franchise but Gilead's entire identity — from a company with the most profitable drug franchise in history to one facing the structural consequences of that franchise's self-limiting design.

This period revealed a structural truth about curative therapies that the pharmaceutical industry had understood theoretically but had never experienced at this scale: cures are medically ideal but commercially self-defeating. Chronic treatments for conditions like HIV, diabetes, or autoimmune disease generate revenue that compounds over time because the patient population accumulates — each new patient adds to the base of existing patients. Curative treatments subtract from the base. The revenue geometry is fundamentally different, and no amount of operational excellence can change the underlying mathematics.

AbbVie's (abbv) competitive entry was particularly consequential. Mavyret, approved in 2017, offered a pan-genotypic cure with an 8-week treatment duration and a significantly lower list price — roughly $26,400 per course. AbbVie's pricing strategy was explicitly designed to win formulary preference from insurers and pharmacy benefit managers who had been resistant to Gilead's higher price points. The competitive dynamics shifted the HCV market from one dominated by Gilead's clinical superiority to one where price and formulary access determined market share. This transition illustrated how even revolutionary drugs are eventually subject to the competitive forces that govern all pharmaceutical markets — differentiation erodes, competitors arrive, and payers exploit the resulting leverage.

Capital Deployment and the Pivot (2016 - 2021)

The HCV windfall generated enormous cash flows during the peak years, and Gilead's capital allocation decisions during and after this period defined the company's subsequent trajectory. The most visible decision was share repurchases. Between 2014 and 2019, Gilead spent over $30 billion on stock buybacks, reducing the outstanding share count substantially. In 2016 alone, the company repurchased approximately $10 billion of its own stock. The buyback program was funded by the HCV cash flows and represented a bet that the stock was undervalued relative to the company's long-term prospects — a bet that proved costly in the near term, as the share price continued declining through much of 2016 and 2017 even as the buyback program consumed billions.

The strategic question Gilead faced was whether to invest the HCV windfall in building new growth engines or return it to shareholders. The company pursued both paths, but the buyback program's scale drew criticism from investors and analysts who argued that the capital would have been better deployed toward acquisitions or pipeline investment during the period when Gilead's pipeline was perceived as thin. The comparison with Amgen's (amgn) buyback-heavy capital allocation strategy is instructive — both companies used aggressive repurchases to support per-share earnings during periods of decelerating growth, and both faced questions about whether the financial engineering was substituting for genuine business building.

The first major strategic acquisition came in October 2017, when Gilead acquired Kite Pharma for $11.9 billion. Kite brought Yescarta (axicabtagene ciloleucel), a CAR-T cell therapy for relapsed or refractory large B-cell lymphoma that had received FDA approval earlier that month. The acquisition signaled Gilead's entry into oncology — a therapeutic area far removed from the company's antiviral roots but one that offered the large addressable markets and long-term growth potential that the declining HCV franchise could not. CAR-T therapy represented a genuinely novel modality: harvesting a patient's own T-cells, genetically engineering them to recognize and attack cancer cells, and reinfusing them. The science was compelling, but the commercial model was unproven at scale, the manufacturing process was complex and personalized, and the treatment was extraordinarily expensive — roughly $373,000 per patient for Yescarta.

The Kite acquisition was a directional bet on cell therapy as a platform, not merely a bet on a single product. Gilead invested in expanding Yescarta's approved indications and developing next-generation CAR-T products. Yescarta's revenue grew steadily, reaching approximately $1.5 billion by 2023. But CAR-T therapy's commercial trajectory proved more modest than early projections had suggested. The personalized manufacturing process limited throughput, the treatment's intensity restricted it to later-line settings where the patient population was smaller, and competing CAR-T products from Bristol-Myers Squibb (Breyanzi and Abecma) and Johnson and Johnson (Carvykti) fragmented the market. Gilead took an $820 million write-down in 2022 when it discontinued development of an anti-BCMA CAR-T candidate, acknowledging that not every cell therapy program would reach the market.

The Oncology Expansion and Immunomedics (2020 - Present)

In September 2020, Gilead made its largest acquisition ever: the purchase of Immunomedics for $21 billion in cash, representing a 108% premium to Immunomedics' prior closing price. The centerpiece of the deal was Trodelvy (sacituzumab govitecan), a first-in-class Trop-2-directed antibody-drug conjugate (ADC) that had received accelerated FDA approval in April 2020 for metastatic triple-negative breast cancer. The acquisition price was aggressive by any measure — Immunomedics had limited commercial infrastructure and Trodelvy was in the early stages of its commercial launch — but Gilead was betting on the ADC platform's potential to expand across multiple solid tumor indications.

Trodelvy's commercial trajectory has been one of steady growth rather than the explosive ramp that characterized the HCV franchise. Sales reached approximately $1.3 billion in 2024, with growth driven by expanding approvals in additional breast cancer subtypes, urothelial carcinoma, and ongoing clinical development in non-small cell lung cancer and other solid tumors. The ADC market has become intensely competitive, with Daiichi Sankyo and AstraZeneca's Enhertu emerging as a formidable competitor and multiple other ADC programs advancing through clinical development. Trodelvy's differentiated mechanism — targeting Trop-2, a different antigen than HER2-targeted ADCs like Enhertu — provides some competitive insulation, but the crowded ADC landscape means that Trodelvy's ultimate commercial potential depends on clinical differentiation in head-to-head competitive settings that have yet to be fully defined.

The combined oncology portfolio — Yescarta, Tecartus (another CAR-T therapy for mantle cell lymphoma), and Trodelvy — generated approximately $3.3 billion in 2024 revenue. This is meaningful revenue, but it represents a fraction of what the HIV franchise contributes. The oncology pivot is real but incomplete: Gilead has built a presence in cancer treatment, but it has not yet built the kind of dominant franchise position in oncology that it holds in HIV. Whether the oncology portfolio can scale to become a structural pillar comparable to the HIV franchise remains the central strategic question facing the company. The contrast with peers is instructive: Merck (mrk) built its oncology franchise around Keytruda, a single checkpoint inhibitor that grew to become the world's best-selling drug, while Gilead has attempted to build its oncology presence through multiple acquired modalities — a broader but more fragmented approach that distributes risk at the cost of concentrated scale in any single product.

HIV Evolution and Lenacapavir (2018 - Present)

While the hepatitis C decline and oncology pivot dominated the narrative, Gilead's HIV franchise quietly evolved into the company's most structurally durable asset. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide), approved in 2018, became the dominant HIV treatment regimen in the United States. By 2024, Biktarvy was generating $13.4 billion in annual revenue and commanding over 50% of the U.S. HIV treatment market — a market share that few single-tablet regimens have achieved in any therapeutic area. The drug's clinical profile — high efficacy, high barrier to resistance, favorable tolerability — combined with Gilead's entrenched relationships with HIV-treating physicians created a competitive position that proved remarkably resilient.

Descovy, the TAF-based successor to Truvada for PrEP, added approximately $2.1 billion in annual revenue and captured a growing share of the prevention market. When Truvada lost patent exclusivity and faced generic competition, Descovy provided a branded alternative with the improved safety profile of the TAF backbone. The transition from Truvada to Descovy in PrEP illustrated Gilead's lifecycle management capability within HIV — the ability to sustain franchise economics by introducing pharmacologically improved successors before patents expire on predecessor products.

The most structurally significant development in Gilead's recent HIV strategy is lenacapavir, a novel capsid inhibitor with a mechanism of action unlike any existing HIV drug. Lenacapavir was initially approved as Sunlenca in 2022 for treatment-experienced patients with multi-drug-resistant HIV. But the transformative application proved to be prevention. In the PURPOSE clinical trials, twice-yearly subcutaneous injections of lenacapavir demonstrated near-perfect efficacy in preventing HIV infection — 100% prevention in the PURPOSE 1 trial among cisgender women in sub-Saharan Africa, and 99.9% prevention in the PURPOSE 2 trial among a diverse global population. The FDA approved lenacapavir for PrEP under the brand name Yeztugo in June 2025, making it the first and only twice-yearly injectable option for HIV prevention.

Yeztugo's structural implications extend beyond incremental franchise revenue. A twice-yearly injection eliminates the daily adherence requirement that limits the effectiveness of oral PrEP — many people at risk of HIV do not take daily pills consistently, and the efficacy of oral PrEP drops dramatically with imperfect adherence. By decoupling prevention from daily behavior, lenacapavir has the potential to expand the effective PrEP population substantially. Gilead has announced partnerships with the Global Fund and PEPFAR to supply lenacapavir at no profit in low- and lower-middle-income countries, positioning the drug as both a commercial product in high-income markets and a global health intervention. The early commercial trajectory — approximately $54 million in the first two quarters following U.S. approval — reflects the typical ramp of a new HIV product, but the addressable market for long-acting PrEP is structurally larger than what daily oral PrEP has captured. The competitive dynamic with ViiV Healthcare's Cabenuva (cabotegravir plus rilpivirine), a long-acting injectable for HIV treatment requiring bimonthly administration, suggests that the market is moving broadly toward less frequent dosing — a trend that favors Gilead's twice-yearly approach if the clinical and access parameters align. Lenacapavir's unique capsid inhibitor mechanism also provides a foundation for potential combination regimens and expanded indications, making it not just a PrEP product but a platform molecule with broader structural significance for Gilead's HIV franchise evolution.